Insights from the Stats Breakthrough Summit

This chapter shares insights from the Stats Breakthrough Summit East in New York, focusing on the advancements in the biotech sector related to MASH treatments. The speakers explore the regulatory landscape for drug development and discuss the potential for accelerated approvals, particularly for patients with severe conditions. Additionally, they examine the current challenges in the gene therapy market and the financial hurdles companies face in commercialization.